Session » Epidemiology & Public Health Poster II

10:30AM-12:30PM

Abstract Number: 1000

Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO

10:30AM-12:30PM

Abstract Number: 0980

Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort

10:30AM-12:30PM

Abstract Number: 0988

Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis

10:30AM-12:30PM

Abstract Number: 0976

Assessment of Current Trends in Demographic and Clinical Characteristics of Male Patients with Rheumatoid Arthritis in North India

10:30AM-12:30PM

Abstract Number: 0994

Association Between Cardiovascular Risk Factors and the Onset of Giant Cell Arteritis: A Systematic Review and Meta-analysis

10:30AM-12:30PM

Abstract Number: 1003

Association Between Metabolic Markers and Knee Osteoarthritis: A Cross-sectional Study Using the Korea National Health and Nutrition Examination Survey 2009 to 2013

10:30AM-12:30PM

Abstract Number: 1006

Associations Between Rheumatic Diseases and Mental Health Disorders

10:30AM-12:30PM

Abstract Number: 0978

Associations of Fire Smoke and Other Pollutants with Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease

10:30AM-12:30PM

Abstract Number: 0999

Clinical and Biological Features of VEXAS Syndrome in Women: Study of 9 French Cases Compared with 263 Men

10:30AM-12:30PM

Abstract Number: 0991

Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations

10:30AM-12:30PM

Abstract Number: 0987

Correlates of Depression in Individuals with Chronic Fatigue Syndrome

10:30AM-12:30PM

Abstract Number: 1007

Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis

10:30AM-12:30PM

Abstract Number: 1002

Depression Screening in Patients with Rheumatologic Diseases in a Large Tertiary Care Center

10:30AM-12:30PM

Abstract Number: 0997

Geographic and Lifestyle Exposures in Systemic Lupus Erythematosus

10:30AM-12:30PM

Abstract Number: 1008

Immune Responses to Infection and Autoimmune Diseases in the UK Biobank

10:30AM-12:30PM

Abstract Number: 1009

Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept

10:30AM-12:30PM

Abstract Number: 0983

Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey

10:30AM-12:30PM

Abstract Number: 0989

Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis

10:30AM-12:30PM

Abstract Number: 0996

Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition

10:30AM-12:30PM

Abstract Number: 0974

Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data

10:30AM-12:30PM

Abstract Number: 1001

Perceived Mistreatment in Patients with Rheumatic Diseases: The Impact of the Underlying Diagnosis

10:30AM-12:30PM

Abstract Number: 1005

Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib

10:30AM-12:30PM

Abstract Number: 0984

Predicting Risk of Infection in Hospitalized Patients with Rheumatic Diseases from the MIMIC-IV Clinical Database: A Machine Learning Approach

10:30AM-12:30PM

Abstract Number: 0990

Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis

10:30AM-12:30PM

Abstract Number: 1004

Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States

10:30AM-12:30PM

Abstract Number: 0975

Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica

10:30AM-12:30PM

Abstract Number: 0993

Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis

10:30AM-12:30PM

Abstract Number: 0985

Specific Causes for Hospitalization in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review

10:30AM-12:30PM

Abstract Number: 0986

State-and-County-Level Social Vulnerability Index and Trends in Systemic Lupus Erythematosus-Related Mortality in the U.S

10:30AM-12:30PM

Abstract Number: 0981

The Causal Effect of Sex Hormone-related Drugs on the Risk of Osteoarthritis – A Mendelian Randomization Study

10:30AM-12:30PM

Abstract Number: 0979

The Joint Project: A Community-Based, Barangay Health Worker-Led Screening Program for Childhood Musculoskeletal Disorders in a Barangay in San Pedro, Laguna, Philippines

10:30AM-12:30PM

Abstract Number: 1010

Total Cost Risk Scores and Barrier Categories in Patients with Axial Spondyloarthritis and Associated Factors

10:30AM-12:30PM

Abstract Number: 0998

Trends and Disparities in Cardiovascular Deaths in Systemic Lupus Erythematosus: A Population-Based Retrospective Study in the United States from 1999 to 2021

10:30AM-12:30PM

Abstract Number: 0982

Urinary Incontinence Among Individuals with Systemic Lupus Erythematosus

10:30AM-12:30PM

Abstract Number: 1011

Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster

10:30AM-12:30PM

Abstract Number: 0977

Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older

10:30AM-12:30PM

Abstract Number: 0992

Visceral Adipose Tissue Measured by DXA Predicts Metabolic Syndrome in Low-Income Community-Dwelling Elderly: Insights from the São Paulo Ageing & Health (SPAH) Study

10:30AM-12:30PM

Abstract Number: 0995

What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?